HUE053449T2 - Kompozíciók, amelyek tartalmazzák lizinspecifikus demetiláz-1 inhibitorát, amelynek van pirimidingyûrûje és azok felhasználása rák kezelésében - Google Patents
Kompozíciók, amelyek tartalmazzák lizinspecifikus demetiláz-1 inhibitorát, amelynek van pirimidingyûrûje és azok felhasználása rák kezelésébenInfo
- Publication number
- HUE053449T2 HUE053449T2 HUE16863111A HUE16863111A HUE053449T2 HU E053449 T2 HUE053449 T2 HU E053449T2 HU E16863111 A HUE16863111 A HU E16863111A HU E16863111 A HUE16863111 A HU E16863111A HU E053449 T2 HUE053449 T2 HU E053449T2
- Authority
- HU
- Hungary
- Prior art keywords
- lysine
- cancer
- inhibitor
- compositions
- treatment
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
- 239000004472 Lysine Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000000714 pyrimidinyl group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562251507P | 2015-11-05 | 2015-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE053449T2 true HUE053449T2 (hu) | 2021-06-28 |
Family
ID=58662888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE16863111A HUE053449T2 (hu) | 2015-11-05 | 2016-11-04 | Kompozíciók, amelyek tartalmazzák lizinspecifikus demetiláz-1 inhibitorát, amelynek van pirimidingyûrûje és azok felhasználása rák kezelésében |
Country Status (21)
Country | Link |
---|---|
US (4) | US9828358B2 (hu) |
EP (1) | EP3371152B1 (hu) |
JP (1) | JP6995043B2 (hu) |
CN (1) | CN108473442B (hu) |
AR (1) | AR106612A1 (hu) |
AU (1) | AU2016349707B2 (hu) |
CA (1) | CA3004300C (hu) |
CY (1) | CY1124078T1 (hu) |
DK (1) | DK3371152T3 (hu) |
ES (1) | ES2846951T3 (hu) |
HR (1) | HRP20210144T8 (hu) |
HU (1) | HUE053449T2 (hu) |
LT (1) | LT3371152T (hu) |
MX (2) | MX2020004894A (hu) |
PL (1) | PL3371152T3 (hu) |
PT (1) | PT3371152T (hu) |
RS (1) | RS61404B1 (hu) |
SI (1) | SI3371152T1 (hu) |
SM (1) | SMT202100044T1 (hu) |
TW (1) | TW201720808A (hu) |
WO (1) | WO2017079670A1 (hu) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016025248B1 (pt) | 2014-05-01 | 2022-12-13 | Celgene Quanticel Research, Inc | Compostos inibidores de demetilase lisina-específica-1, composição farmacêutica e seus usos |
CA3004300C (en) * | 2015-11-05 | 2023-08-22 | Celgene Quanticel Research, Inc. | Compositions comprising an inhibitor of lysine specific demethylase-1 |
US20190256930A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
EP3551178A1 (en) | 2016-12-09 | 2019-10-16 | Constellation Pharmaceuticals, Inc. | Markers for personalized cancer treatment with lsd1 inhibitors |
DK3661510T3 (da) | 2017-08-03 | 2025-01-02 | Oryzon Genomics Sa | Fremgangsmåder til behandling af adfærdsændringer |
CN113631164A (zh) | 2019-03-20 | 2021-11-09 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
SG11202109159VA (en) | 2019-03-20 | 2021-10-28 | Oryzon Genomics Sa | Methods of treating borderline personality disorder |
CN115135324A (zh) * | 2019-06-13 | 2022-09-30 | 细胞基因公司 | 通过靶向冷肿瘤治疗癌症的方法 |
WO2020257665A1 (en) * | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Kdm1a阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
CN116056707A (zh) * | 2020-06-05 | 2023-05-02 | 赛尔基因昆蒂赛尔研究公司 | 治疗前列腺癌的方法 |
ES2919083R1 (es) * | 2020-06-29 | 2022-07-26 | Celgene Quanticel Res Inc | Métodos de tratamiento de cáncer de próstata |
MX2023011779A (es) | 2021-04-08 | 2023-11-22 | Oryzon Genomics Sa | Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides. |
EP4522137A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
CN119546292A (zh) | 2022-05-09 | 2025-02-28 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法 |
WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US7101873B2 (en) * | 2002-04-10 | 2006-09-05 | Bexel Pharmaceuticals Inc. | Pyrimidinedione derivatives |
WO2003084937A2 (en) | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
JP2008515902A (ja) * | 2004-10-06 | 2008-05-15 | エヌピーエス ファーマシューティカルズ インコーポレイテッド | カルシウム拮抗化合物としての相補ピリミジノン化合物 |
US20100137313A1 (en) * | 2008-10-03 | 2010-06-03 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
EP3094627B1 (en) * | 2014-01-17 | 2018-08-22 | Novartis AG | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
BR112016025248B1 (pt) * | 2014-05-01 | 2022-12-13 | Celgene Quanticel Research, Inc | Compostos inibidores de demetilase lisina-específica-1, composição farmacêutica e seus usos |
CA3004300C (en) * | 2015-11-05 | 2023-08-22 | Celgene Quanticel Research, Inc. | Compositions comprising an inhibitor of lysine specific demethylase-1 |
-
2016
- 2016-11-04 CA CA3004300A patent/CA3004300C/en active Active
- 2016-11-04 PL PL16863111T patent/PL3371152T3/pl unknown
- 2016-11-04 RS RS20210094A patent/RS61404B1/sr unknown
- 2016-11-04 PT PT168631117T patent/PT3371152T/pt unknown
- 2016-11-04 MX MX2020004894A patent/MX2020004894A/es unknown
- 2016-11-04 SI SI201631055T patent/SI3371152T1/sl unknown
- 2016-11-04 DK DK16863111.7T patent/DK3371152T3/da active
- 2016-11-04 WO PCT/US2016/060694 patent/WO2017079670A1/en active Application Filing
- 2016-11-04 CN CN201680076854.5A patent/CN108473442B/zh active Active
- 2016-11-04 ES ES16863111T patent/ES2846951T3/es active Active
- 2016-11-04 HU HUE16863111A patent/HUE053449T2/hu unknown
- 2016-11-04 JP JP2018522953A patent/JP6995043B2/ja active Active
- 2016-11-04 LT LTEP16863111.7T patent/LT3371152T/lt unknown
- 2016-11-04 EP EP16863111.7A patent/EP3371152B1/en active Active
- 2016-11-04 US US15/344,426 patent/US9828358B2/en active Active
- 2016-11-04 SM SM20210044T patent/SMT202100044T1/it unknown
- 2016-11-04 MX MX2018005620A patent/MX373363B/es active IP Right Grant
- 2016-11-04 AU AU2016349707A patent/AU2016349707B2/en active Active
- 2016-11-07 AR ARP160103391A patent/AR106612A1/es unknown
- 2016-11-07 TW TW105136105A patent/TW201720808A/zh unknown
-
2017
- 2017-10-25 US US15/793,512 patent/US10047069B2/en active Active
-
2018
- 2018-07-10 US US16/032,002 patent/US10316016B2/en active Active
-
2019
- 2019-06-10 US US16/436,541 patent/US10703739B2/en active Active
-
2021
- 2021-01-27 HR HRP20210144TT patent/HRP20210144T8/hr unknown
- 2021-01-28 CY CY20211100072T patent/CY1124078T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE053449T2 (hu) | Kompozíciók, amelyek tartalmazzák lizinspecifikus demetiláz-1 inhibitorát, amelynek van pirimidingyûrûje és azok felhasználása rák kezelésében | |
HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
HUE054103T2 (hu) | Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása | |
HUE055755T2 (hu) | Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk | |
HUE055233T2 (hu) | Az EGFR gátló és annak elkészítése és alkalmazása | |
ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
HUE046756T2 (hu) | Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei | |
HUE052095T2 (hu) | Keratin kezelési készítmények és eljárások | |
HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
GB201703115D0 (en) | Use of cannabinoids in the treatment of leukaemia | |
IL258259A (en) | Adjunctive therapy with 25-hydroxyvitamin d and articles therefor | |
HUE052223T2 (hu) | IGF-1R ellenanyag és alkalmazása rák kezelésében célzóeszközként | |
HUE036084T2 (hu) | Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél | |
HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
IL249220B (en) | Use of Aribolin in cancer treatment | |
HUE059990T2 (hu) | 2-Oxo-tiazol-származékok A2A inhibitorként és a rákos megbetegedések kezelésében alkalmazható vegyületekként | |
HUE062784T2 (hu) | Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében | |
HUE053927T2 (hu) | Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra | |
HUE045025T2 (hu) | Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére | |
HUE045192T2 (hu) | 6-morfolinil-2-pirazolil-9H-purin származékok és felhasználásuk PI3K inhibitorokként | |
HK1245113A1 (zh) | 藥物組合物及其用途 | |
HUE058652T2 (hu) | Vegyületek és felhasználásuk a schisotosomiasis kezelésében | |
PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
HUE047272T2 (hu) | Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére | |
IL266659B (en) | Fgfr4 inhibitor, pharmaceutical composition comprising it and use thereof |